How Long Does Perimenopause Last? Signs That It's Ending

What Perimenopause Actually Is and How Long It Lasts

Perimenopause is the transitional window between regular ovulatory cycles and menopause. It is not a single event. The STRAW+10 staging system, published in 2012 and endorsed by the American Society for Reproductive Medicine, North American Menopause Society, and multiple international bodies, divides the reproductive aging continuum into stages numbered from -5 (peak reproductive years) through +2 (late postmenopause). Perimenopause spans stages -2 (early menopausal transition) through -1 (late menopausal transition) [1].

The Study of Women's Health Across the Nation (SWAN), a multiethnic longitudinal cohort of 3,302 women followed for over 16 years, found that the median total duration of the menopausal transition was approximately 4.8 years from onset of cycle irregularity to the final menstrual period [2]. Some participants completed the transition in under 2 years. Others remained in perimenopause for more than 11 years.

Race and ethnicity influenced duration. SWAN data showed that Black women experienced a longer transition (median ~10 years of vasomotor symptoms) compared with Japanese and Chinese women, who had shorter symptom windows [2]. Body mass index, smoking status, and stress levels also affected timing. Women who smoked reached menopause roughly 1 to 2 years earlier than nonsmokers, according to a meta-analysis of 109 studies published in Maturitas [3].

The average age at which menopause occurs in the United States is 51.4 years [4]. Early perimenopause can begin in the late 30s or early 40s. If you are 44 and noticing your cycle length shifting from 28 days to 21 or 38 days unpredictably, that variability is the hallmark entry point.

The Two Phases of Perimenopause: Early vs. Late

The STRAW+10 system splits perimenopause into two clinically distinct phases. Understanding which phase you are in helps predict how far you are from the finish line.

Early menopausal transition (Stage -2): Cycles become variable. The defining criterion is a persistent difference of 7 or more days in cycle length compared to your baseline. You may still ovulate most months. Estradiol levels can swing higher than premenopausal peaks before dropping, which is why some women experience worsening PMS, heavier bleeding, or new-onset migraines during this phase [1]. FSH begins to rise but may still fall within the "normal" premenopausal range on any given draw.

Late menopausal transition (Stage -1): You begin skipping periods entirely. The STRAW+10 criterion is an interval of 60 or more days of amenorrhea. FSH levels climb above 25 mIU/mL. Ovulation becomes rare. This phase typically lasts 1 to 3 years. Vasomotor symptoms (hot flashes, night sweats) tend to emerge or intensify here. A 2015 JAMA Internal Medicine analysis of SWAN data showed that the median total duration of frequent vasomotor symptoms was 7.4 years, and women who began experiencing hot flashes during this late transition phase had the longest symptom duration [5].

The distinction matters for treatment planning. Women in early transition may benefit from low-dose oral contraceptives for both cycle regulation and symptom control. Women in late transition are often better served by menopausal hormone therapy at standard or low doses.

Seven Clinical Signs That Perimenopause Is Ending

Perimenopause does not end with a single definitive moment. It tapers. These signs, taken together, suggest you are approaching or have reached the final menstrual period.

1. Periods space out beyond 60 days. This is the single most reliable clinical marker of late-stage transition. When you go two or more months between bleeds repeatedly, the end is statistically within 1 to 3 years [1].

2. FSH stays elevated on repeat testing. A single FSH above 25 mIU/mL can reflect a transient spike. Two values above 25 mIU/mL, drawn 4 to 6 weeks apart, are more meaningful. The Endocrine Society's 2015 clinical practice guideline notes that FSH above 25 to 30 mIU/mL in the context of menstrual irregularity supports the diagnosis of late perimenopause [6]. An FSH above 40 mIU/mL on repeated draws, combined with amenorrhea, is consistent with menopause.

3. Hot flashes and night sweats intensify temporarily. It seems counterintuitive, but vasomotor symptoms frequently peak in the 1 to 2 years surrounding the final menstrual period. SWAN data confirmed this: the highest-frequency hot flash window was centered on the final menstrual period, not years before it [5].

4. Sleep disruption worsens before stabilizing. A 2017 study in Sleep found that self-reported sleep difficulty peaked in the late transition and early postmenopause, then partially improved after 2 to 3 years of stable postmenopausal status [7]. If your sleep has been deteriorating for months and your periods are rare, you may be close to the final period.

5. Vaginal dryness becomes persistent. Unlike hot flashes, which are episodic, genitourinary symptoms of menopause (GSM) tend to be progressive. The North American Menopause Society position statement on GSM notes that vaginal pH rises above 5.0, epithelial tissue thins, and lubrication declines as estrogen withdrawal becomes sustained [8]. Persistent vaginal dryness without cyclical improvement suggests estrogen is no longer rebounding between periods.

6. Mood symptoms shift character. Early perimenopause is associated with anxiety-predominant mood changes; late perimenopause and early postmenopause are more commonly linked to depressive symptoms. A 2019 review in The Lancet highlighted that the risk of a first-lifetime depressive episode doubles during the late menopausal transition compared to premenopausal years [9]. If your predominant mood complaint has shifted from irritability and anxiety toward low mood and fatigue, you may be in the final stretch.

7. Your periods, when they come, are lighter. After years of unpredictable, sometimes heavy bleeding, many women notice their final few periods are shorter and lighter. This reflects a thinner endometrial lining driven by consistently low estradiol without the erratic surges of earlier perimenopause.

No single sign is diagnostic on its own. The pattern matters. Three or more of these changes occurring together over 6 to 12 months is strongly suggestive that the transition is nearing completion.

What Lab Tests Confirm the Transition

Lab testing during perimenopause is notoriously tricky because hormone levels fluctuate day to day. A "normal" estradiol drawn on Monday can plummet by Thursday. Clinicians and patients need to interpret labs as trends, not snapshots.

FSH (follicle-stimulating hormone): The most commonly ordered marker. In active perimenopause, FSH can range from 10 to 50 mIU/mL within a single cycle. Two values above 30 mIU/mL drawn at least 4 weeks apart, in the setting of amenorrhea exceeding 60 days, strongly suggest late-stage transition. The 2015 Endocrine Society guideline cautions against using a single FSH value to diagnose menopause in women aged 40 to 45 [6].

Estradiol: Late perimenopause often shows values below 50 pg/mL, but individual draws can spike to 200+ pg/mL during a follicular recruitment attempt. Persistently low estradiol (below 20 pg/mL) on two or more draws, combined with elevated FSH, suggests the ovarian reserve is near depletion.

Anti-Müllerian hormone (AMH): AMH reflects remaining ovarian follicle pool and declines to undetectable levels (<0.1 ng/mL) around the time of the final menstrual period. A 2014 study in the Journal of Clinical Endocrinology & Metabolism found AMH was the single best predictor of time to final menstrual period, outperforming FSH and inhibin B [10]. An undetectable AMH in a woman over 45 with irregular cycles predicts menopause within approximately 5 years. If AMH is undetectable and FSH is above 25 mIU/mL, the final period may be within 1 to 2 years.

Thyroid panel (TSH, free T4): Not a menopause marker, but thyroid dysfunction mimics perimenopause symptoms closely. The American Thyroid Association recommends screening women over 35 every 5 years, and any new evaluation for perimenopausal symptoms should include TSH [11].

Dr. Nanette Santoro, professor of obstetrics and gynecology at the University of Colorado School of Medicine and principal investigator of the SWAN study, has stated: "There is no single blood test that tells a woman she is in perimenopause or tells her when it will end. We rely on the clinical picture: irregular cycles, symptoms, and the trend of FSH over time" [5].

How Hormone Therapy Changes as Perimenopause Ends

The approach to hormone therapy (HT) should evolve as a woman moves from early to late perimenopause and into postmenopause. A regimen that made sense at 43 may need recalibration at 52.

During early perimenopause, many clinicians prescribe combined oral contraceptives (COCs) for women who also need contraception. COCs regulate cycles, reduce heavy bleeding, and suppress vasomotor symptoms. The ACOG Practice Bulletin on perimenopause supports COC use in healthy, nonsmoking women until the age of natural menopause [12].

During late perimenopause, the shift to menopausal HT typically occurs. Standard regimens include transdermal estradiol (0.025 to 0.05 mg/day patch) plus micronized progesterone (100 to 200 mg nightly) for women with an intact uterus. The 2022 North American Menopause Society position statement reaffirmed that HT remains the most effective treatment for vasomotor symptoms and should be considered for symptomatic women under 60 or within 10 years of menopause onset [13].

At menopause confirmation (12 months amenorrhea), the transition is complete. Clinicians may adjust dosing based on symptom response rather than lab targets. The 2022 NAMS statement notes: "The goal is the lowest effective dose for the shortest duration consistent with treatment goals and quality of life, individualized for each woman" [13].

For women who cannot or prefer not to use hormones, nonhormonal alternatives include fezolinetant (Veozah), a neurokinin 3 receptor antagonist approved by the FDA in May 2023. In the phase 3 SKYLIGHT 1 trial (N=500), fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 61.3% at week 12 compared with 40.4% for placebo [14].

What Happens to Your Body After Perimenopause Ends

Once the final menstrual period has passed, the postmenopausal body enters a new steady state. Some changes are immediate. Others unfold over years.

Bone density declines fastest in the first 1 to 3 years postmenopause. A longitudinal analysis from the Study of Osteoporotic Fractures found that women lost an average of 1.5% to 2.5% of lumbar spine bone mineral density per year during the transmenopause window [15]. This rate slows after 3 to 5 years. The U.S. Preventive Services Task Force recommends DEXA screening for all women at age 65, or earlier in those with risk factors [16].

Cardiovascular risk rises. The loss of endogenous estradiol removes a relative cardioprotective effect. LDL cholesterol increases by an average of 10 to 15% in the 2 years surrounding the final menstrual period, while HDL may decrease [17]. Women should have lipid panels checked annually in the early postmenopause years.

Vasomotor symptoms may persist. SWAN data showed that roughly 42% of women were still experiencing frequent hot flashes 4 to 5 years after their final menstrual period [5]. The assumption that hot flashes vanish quickly after menopause is a clinical myth.

Genitourinary symptoms tend to worsen. Unlike hot flashes, which can improve over years, vaginal atrophy, urinary urgency, and recurrent UTIs often progress without treatment. Low-dose vaginal estrogen (estradiol 10 mcg insert, twice weekly) is effective and carries minimal systemic absorption, per NAMS 2020 guidance [8].

When to Talk to Your Doctor

Cycle irregularity before age 40 warrants evaluation for primary ovarian insufficiency (POI), not assumed perimenopause. POI affects approximately 1% of women and requires different management, including earlier initiation of HT for bone and cardiovascular protection [6].

Heavy bleeding that soaks through a pad or tampon hourly for more than 2 hours should be evaluated urgently. Endometrial biopsy is recommended for women over 45 with abnormal uterine bleeding, or over 35 with risk factors such as obesity or chronic anovulation, per ACOG guidelines [12].

Mood symptoms that interfere with daily function, especially new-onset depression during late perimenopause, should prompt a conversation about both HT and SSRIs. The 2018 NAMS/ISSWSH consensus statement supports HT as a treatment for perimenopausal depression in appropriate candidates [18].

Any vaginal bleeding after 12 months of confirmed amenorrhea (postmenopausal bleeding) requires evaluation to rule out endometrial pathology, including hyperplasia and carcinoma.